Merus to price its IPO of 4,333,333 shares between $14.00 and $16.00

Citigroup and Jefferies are bookrunners; Guggenheim and Wedbush assist

By Devika Patel

Knoxville, Tenn., May 9 – Merus BV will sell 4,333,333 common shares in its initial public offering with a greenshoe option of 650,000 additional shares, according to a Form F-1/A filed Monday with the Securities and Exchange Commission. The company has registered up to $79,733,328 of stock for the deal, which was announced on Oct. 19.

The shares will be sold at a price expected to fall between $14.00 and $16.00 per share.

Citigroup and Jefferies are the bookrunners. Guggenheim Securities is the lead manager and Wedbush PacGrow is the co-manager.

Proceeds will be used for clinical development, research and development activities and for working capital and other general corporate purposes.

The immuno-oncology company is based in Utrecht, the Netherlands. The company intends to list its common stock on the Nasdaq stock exchange under the symbol “MRUS.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.